Amcasertib

INN name:	Amcasertib
Chemical name:	N-[2-(diethylamino)ethyl]-2,4-dimethyl-5-{[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1,2-dihydro-3H-indol-3-ylidene]methyl}-1H-pyrrole-3-carboxamide
Molecular formula:	C31H33N5O2S
Chemical Structure:
CAS Registry Number:	1129403-56-0
Originator:	Boston Biomedical
Class:	Antineoplastic
WHO ATC code:	L01 (Antineoplastic Agents)
EPhMRA code:	L1 (Antineoplastics)
FDA approval:	Not yet approved
Product Patent Expiry: USA September 2028 South Korea Not entered national phase yet. Canada September 2028* (application under examination) China September 2028 Japan September 2028 * The expiry date is based on the application filing, granted patent expiry may differ from the date mentioned. It is possible to extend the term of a patent in USA, KR and JP. The extension granted at the time of writing this post has been included and marked with **. Please leave a comment below for any update.
Recent activities on the drug: